PURPOSE: PulmoSphere particles are specifically engineered for delivery by the pulmonary route with a hollow and porous morphology, physical diameters < 5 microm, and low tap densities (circa 0.1 g x cm(-3)). Deposition of PulmoSphere particles in the human respiratory tract delivered by pressurized metered dose inhaler (pMDI) was compared with deposition of a conventional micronized drug pMDI formulation. METHODS:Nine healthy nonsmoking subjects (5 male, 4 female) completed a two-way crossover gamma scintigraphic study, assessing the lung and oropharyngeal depositions of albuterol sulfate, formulated as 99mTc-radiolabeled PulmoSphere particles or micronized particles (Ventolin Evohaler, GlaxoSmithKline, Ltd.) suspended in HFA-134a propellant. RESULTS:Mean (standard deviation) lung deposition, (% ex-valve dose) was doubled for the PulmoSphere formulation compared with Evohaler pMDI (28.5 (11.3) % vs. 14.5 (8.1) %, P < 0.01), whereas oropharyngeal deposition was reduced (42.6 (9.0) % vs. 72.0 (8.0) %, P < 0.01). Both PulmoSphere and Evohaler pMDIs gave uniform deposition patterns within the lungs. CONCLUSIONS: These data provided "proof of concept" in vivo for the PulmoSphere technology as a method of improving targeting of drugs to the lower respiratory tract from pMDIs, and suggested that the PulmoSphere technology may also be suitable for the delivery of systemically acting molecules absorbed via the lung.
RCT Entities:
PURPOSE: PulmoSphere particles are specifically engineered for delivery by the pulmonary route with a hollow and porous morphology, physical diameters < 5 microm, and low tap densities (circa 0.1 g x cm(-3)). Deposition of PulmoSphere particles in the human respiratory tract delivered by pressurized metered dose inhaler (pMDI) was compared with deposition of a conventional micronized drug pMDI formulation. METHODS: Nine healthy nonsmoking subjects (5 male, 4 female) completed a two-way crossover gamma scintigraphic study, assessing the lung and oropharyngeal depositions of albuterol sulfate, formulated as 99mTc-radiolabeled PulmoSphere particles or micronized particles (Ventolin Evohaler, GlaxoSmithKline, Ltd.) suspended in HFA-134a propellant. RESULTS: Mean (standard deviation) lung deposition, (% ex-valve dose) was doubled for the PulmoSphere formulation compared with Evohaler pMDI (28.5 (11.3) % vs. 14.5 (8.1) %, P < 0.01), whereas oropharyngeal deposition was reduced (42.6 (9.0) % vs. 72.0 (8.0) %, P < 0.01). Both PulmoSphere and Evohaler pMDIs gave uniform deposition patterns within the lungs. CONCLUSIONS: These data provided "proof of concept" in vivo for the PulmoSphere technology as a method of improving targeting of drugs to the lower respiratory tract from pMDIs, and suggested that the PulmoSphere technology may also be suitable for the delivery of systemically acting molecules absorbed via the lung.
Authors: L A Dellamary; T E Tarara; D J Smith; C H Woelk; A Adractas; M L Costello; H Gill; J G Weers Journal: Pharm Res Date: 2000-02 Impact factor: 4.200
Authors: S J Farr; S J Warren; P Lloyd; J K Okikawa; J A Schuster; A M Rowe; R M Rubsamen; G Taylor Journal: Int J Pharm Date: 2000-03-30 Impact factor: 5.875
Authors: D A Edwards; J Hanes; G Caponetti; J Hrkach; A Ben-Jebria; M L Eskew; J Mintzes; D Deaver; N Lotan; R Langer Journal: Science Date: 1997-06-20 Impact factor: 47.728
Authors: James B Fink; Lisa Molloy; John S Patton; Valdecir Castor Galindo-Filho; Jacqueline de Melo Barcelar; Luciana Alcoforado; Simone Cristina Soares Brandão; Armèle Dornelas de Andrade Journal: Pharm Res Date: 2017-07-17 Impact factor: 4.200
Authors: Catherine H Richardson; Marcel de Matas; Harold Hosker; Rahul Mukherjee; Ian Wong; Henry Chrystyn Journal: Pharm Res Date: 2007-05-18 Impact factor: 4.200
Authors: Hilliard L Kutscher; Piyun Chao; Manjeet Deshmukh; Yashveer Singh; Peidi Hu; Laurie B Joseph; David C Reimer; Stanley Stein; Debra L Laskin; Patrick J Sinko Journal: J Control Release Date: 2010-01-05 Impact factor: 9.776